ストックスクリーナーアプリを入手
2.87
0.00%
0.00
アフターアワーズ：
2.95
0.08
+2.79%
前日終値:
$2.87
開ける：
$2.89
24時間の取引高:
2.38M
Relative Volume:
2.44
時価総額：
$364.24M
収益：
$433.14M
当期純損益:
$4.95M
株価収益率:
80.39
EPS:
0.0357
ネットキャッシュフロー:
$6.55M
1週間 パフォーマンス:
-30.17%
1か月 パフォーマンス:
-26.41%
6か月 パフォーマンス:
-42.94%
1年 パフォーマンス:
-43.06%
1日の値動き範囲:
$2.85
$2.995
1週間の範囲:
$2.81
$4.13
52週間の値動き範囲:
$2.6101
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Compare ORGO vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.87 | 364.24M | 433.14M | 4.95M | 6.55M | 0.0357 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-28 | 開始されました | Lake Street | Buy |
| 2024-02-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-06-15 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-05-24 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-10 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-08-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-08-26 | 再開されました | Credit Suisse | Outperform |
| 2019-05-02 | 開始されました | Credit Suisse | Outperform |
| 2019-04-17 | 開始されました | Oppenheimer | Outperform |
| 2019-04-11 | 開始されました | SunTrust | Buy |
すべてを表示
Organogenesis Holdings Inc (ORGO) 最新ニュース
Organogenesis (ORGO) VP amends Form 4 for equity grant and tax withholding - Stock Titan
ORGO (Organogenesis) CEO amends Form 4 for stock grant and tax share disposal - Stock Titan
[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity - Stock Titan
Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares - Stock Titan
Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares - Stock Titan
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2025 Earnings Call Transcript - Insider Monkey
ORGO PE Ratio & Valuation, Is ORGO Overvalued - Intellectia AI
Wall Street Zen Downgrades Organogenesis (NASDAQ:ORGO) to Hold - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Unveiling a Potential 116% Upside in Healthcare Innovation - DirectorsTalk Interviews
Organogenesis (ORGO) CAO files Form 3 detailing stock and RSUs - Stock Titan
Organogenesis (NASDAQ:ORGO) Price Target Cut to $8.00 by Analysts at BTIG Research - MarketBeat
Organogenesis Holdings (ORGO) Margin-Driven Profitability Shift Tests Revenue Concern Narratives - Sahm
Organogenesis Q4 Earnings Call Highlights - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ... - Investing.com Canada
Organogenesis (ORGO) Q4 2025 Earnings Transcript - AOL.com
ORGO: Record Q4 revenue, but 2026 guidance signals a sharp decline before expected recovery - TradingView
Organogenesis: Q4 Earnings Snapshot - Barchart.com
Earnings call transcript: Organogenesis Q4 2025 beats expectations but faces market challenges - Investing.com UK
Organogenesis Holdings Inc. (ORGO) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
ORGO: Record 2025 results, but 2026 revenue expected to decline due to CMS changes before recovery - TradingView
Wound-care firm Organogenesis hits record sales, warns 2026 drop up to 38% - Stock Titan
Organogenesis Holdings Q4 Earnings Report: What Investors Need to Know - Sahm
A Preview Of Organogenesis Hldgs's Earnings - Benzinga
Published on: 2026-02-25 08:32:12 - baoquankhu1.vn
Organogenesis Holdings Inc expected to post earnings of 21 cents a shareEarnings Preview - TradingView
Organogenesis Names Patrick McGuire Chief Accounting Officer - The Globe and Mail
Organogenesis (Nasdaq: ORGO) appoints Patrick McGuire as CAO - Stock Titan
Organogenesis Holdings Inc. Announces Executive Changes, Effective February 18, 2026 - marketscreener.com
Organogenesis (NASDAQ: ORGO) legal chief granted options, RSUs and settles taxes - Stock Titan
Executive equity awards at Organogenesis (ORGO) include RSUs, options and tax withholding - Stock Titan
Organogenesis Holdings (NASDAQ: ORGO) COO gets new stock and option awards - Stock Titan
Equity grant gives Organogenesis (ORGO) director 48,828 RSUs vesting 2027 - Stock Titan
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
48,828 RSUs granted to Organogenesis (ORGO) director Arthur Leibowitz - Stock Titan
What’s the fair value of Organogenesis Holdings Inc. stockJuly 2025 Price Swings & Verified Momentum Stock Ideas - mfd.ru
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a 113% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 - The Manila Times
Regenerative medicine firm Organogenesis sets Feb. 26 call on 2025 results - Stock Titan
Organogenesis (NASDAQ: ORGO) VP uses 18,619 shares to cover tax liability - Stock Titan
Published on: 2026-02-18 01:47:23 - mfd.ru
Organogenesis (NASDAQ: ORGO) holder First Light reports 2.85% stake - Stock Titan
Will Organogenesis Holdings Inc. benefit from rate cutsTrade Exit Report & Reliable Breakout Forecasts - mfd.ru
ORGO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Organogenesis Holdings Inc. (ORGO) Stock Analysis: A Compelling 127% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
ORGO Should I Buy - Intellectia AI
Is Organogenesis Holdings Inc. benefiting from innovation trends2025 Growth vs Value & Target Return Focused Stock Picks - mfd.ru
Soleus group holds 9.99M Organogenesis (ORGO) shares in passive stake - Stock Titan
Aug Analyst Calls: Is Organogenesis Holdings Inc. stock in correction or buying zoneTrade Risk Report & Fast Exit and Entry Trade Guides - mfd.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vizsla Silver Corp. - GlobeNewswire Inc.
Is Organogenesis Holdings Inc impacted by rising ratesWeekly Trade Summary & Long Hold Capital Preservation Tips - baoquankhu1.vn
Organogenesis Holdings Inc (ORGO) 財務データ
収益
当期純利益
現金流量
EPS
0.21%
1.77%
大文字化:
|
ボリューム (24 時間):